Jefferies analyst David Steinberg believes shares of Pacira Pharmaceuticals could be positioned for a rebound after Symphony Health data indicated Exparel posted "well above trend growth" in February. Sales were $24M, up 3.4% from last month and up 12.6% year-over-year, according to Symphony. The data have shown double digit year-over-years gains in four of the past five months, versus just one of nine months prior, Steinberg tells investors in a research note. He believes Pacira is attractively valued at current levels and keeps a Buy rating on the shares with a $49 price target.